Tezosentan in patients with acute heart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (RITZ-4)

Journal of the American College of Cardiology

Volumn 41, Issue 9, 2003, Pages 1452-1457

  O'Connor, Christopher M ^a   Gattis, Wendy A ^a,g   Adams Jr , Kirkwood F ^b   Hasselblad, Vic ^a   Chandler, Bleakley ^c   Frey, Aline ^d   Kobrin, Isaac ^d   Rainisio, Maurizio ^d   Shah, Monica R ^a   Teerlink, John ^e   Gheorghiade, Mihai ^f  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University Hospital Augusta   (United States)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TEZOSENTAN;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; KAPLAN MEIER METHOD; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; THORAX PAIN; TREATMENT OUTCOME; VERTIGO;

EID: 0038414660     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00194-3     Document Type: Article

References (26)

1. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2001.
2. Cuffe MS, Califf RM, Adams KF Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure. JAMA 2002;287:1541-7.
3. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J 1999;138:95-9.
4. Chen YN, Wei JR, Zeng LJ, Wu MY. Monitoring of cardiac troponin I in patients with acute heart failure. Ann Clin Biochem 1999;36:433-7.
5. Mossov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96:2953-8.
6. Del Carlo C, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999;138:646-53.
7. Setsuta K, Seino Y, Takahashi N, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999;84:608-11.
8. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
9. O'Connor CM, Gattis WA, Adams KF Jr., et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan (RITZ-4) study. Am Heart J 2002;144:583-8.
10. Clozel M, Ramuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exper Ther 1999;290:840-6.
11. Love MP, McMurray JJV. Endothelin in chronic heart failure: current position and future prospects. Cardiovasc Res 1996;31:665-74.
12. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol 2000;72:175-86.
13. Pousset F, Isnard R, Lechat P, et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997;18:254-8.
14. Pernow J, Wang QD. Endothlin in myocardial ischemia and reperfusion. Cardiovasc Res 1997;33:518-26.
15. Omland T, Lie RT, Aakvaag A, et al. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994;89:1573-9.
16. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
17. Stewart DJ, Kubac G, Costello KB, et al. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991;18:38-43.
18. Ray SG, McMurray JJ, Mortaon JJ, et al. Circulating endothelin in acute ischemic syndromes. Br Heart J 1992;67:383-6.
19. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994;89:1580-6.
20. Ponicke K, Vogelsang M, Heinroth M, et al. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998;97:744-51.
21. Nakamura M, Arakawa N, Hoshida H, et al. Increased plasma endothelin concentrations in patients with acute heart failure after myocardial infarction. Jpn Circ J 1993;57:371-8.
22. Cotter G, Kiowski W, Kaluski E, et al. Tezosentan (the first i.v. endothelin receptor A/B antagonist) reduces peripheral resistance and increases myocardial contractility despite reducing left ventricular filling (wedge) pressure in patients with congestive heart failure (abstr). Eur Heart J 2000;21 Suppl:297.
23. Schalcher C, Mandinov L, Schindler R, et al. Dose dependency of haemodynamic changes to the endothelin-receptor antagonist tezosentan in patients with heart failure (abstr). Eur Heart J 2000;21 Suppl:116.
24. Torre-Amione G, Durand JB, Nagueh S, et al. A pilot safety trial of prolonged (48-hour) infusion of the dual endothelin receptor antagonist tezosentan in patients with advanced heart failure. Chest 2001;120:460-6.
25. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACL, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology. Eur J Heart Fail 2001;3:381-7.
26. Coletta AP, Cleland JG. Clinical trials update: highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001;3:747-50.